drugset / Trial / NCT00631319
A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
Timeline
- Start
- 2008-02
- Primary completion
- 2009-04
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydromorphone | Other / unclassified | 12 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 16 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 24 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 32 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 40 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 48 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 64 mg | Oral |